Corrigendum to “Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240]

IF 4.7 4区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Nanomedicine: Nanotechnology, Biology and Medicine Pub Date : 2023-07-01 DOI:10.1016/j.nano.2023.102690

Ali Masjedi MSc , Armin Ahmadi PhD , Sepideh Ghanee PhD , Farinaz Malakotikhah PhD , Mohsen Nabi Afjadi PhD , Mahzad Irandoust PhD , Fariba Karoon Kiani MSc , Sima Heydarzadeh Asl MSc , Fatemeh Atyabi PhD , Hadi Hassannia PhD , Mohammad Hojjat-Farsangi PhD , Afshin Namdar PhD , Ghasem Ghalamfarsa PhD , Farhad Jadidi-Niaragh PhD

引用次数: 0

查看原文本刊更多论文

“沉默腺苷A2a受体增强树突状细胞为基础的癌症免疫治疗”的更正[纳米医学纳米技术生物医学29 (2020)102240]

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nanomedicine: Nanotechnology, Biology and Medicine 医学-纳米科技

CiteScore

8.10

自引率

3.60%

发文量

104

审稿时长

4.6 months

期刊介绍： Nanomedicine: Nanotechnology, Biology and Medicine (NBM) is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life and health sciences. Content includes basic, translational, and clinical research addressing diagnosis, treatment, monitoring, prediction, and prevention of diseases.